Listed

vTv Therapeutics Inc.

VTVTNasdaqCIK 1641489HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$13.9m, Q2 FY2026
Net income−$13.1m, Q2 FY2026
vTv Therapeutics Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure1.0Revenue, Q1 FY2024, three months to 2024-03-31$1.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure36.8Revenue, Q1 FY2026, three months to 2026-03-31$36.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Research and development$m2.8Research and development, Q3 FY2023, three months to 2023-09-30$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure2.1Research and development, Q4 FY2023, three months to 2023-12-31$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure2.6Research and development, Q1 FY2024, three months to 2024-03-31$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure3.4Research and development, Q2 FY2024, three months to 2024-06-30$3.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure3.2Research and development, Q3 FY2024, three months to 2024-09-30$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure2.2Research and development, Q4 FY2024, three months to 2024-12-31$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure2.8Research and development, Q1 FY2025, three months to 2025-03-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure4.1Research and development, Q2 FY2025, three months to 2025-06-30$4.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure7.0Research and development, Q3 FY2025, three months to 2025-09-30$7.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure3.9Research and development, Q4 FY2025, three months to 2025-12-31$3.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure9.0Research and development, Q1 FY2026, three months to 2026-03-31$9.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure8.8Research and development, Q2 FY2026, three months to 2026-06-30$8.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Operating income$m(5.4)Operating income, Q3 FY2023, three months to 2023-09-30−$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure(4.7)Operating income, Q4 FY2023, three months to 2023-12-31−$4.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure(5.6)Operating income, Q1 FY2024, three months to 2024-03-31−$5.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure(7.2)Operating income, Q2 FY2024, three months to 2024-06-30−$7.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure(6.5)Operating income, Q3 FY2024, three months to 2024-09-30−$6.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure(4.9)Operating income, Q4 FY2024, three months to 2024-12-31−$4.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure(6.5)Operating income, Q1 FY2025, three months to 2025-03-31−$6.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure(7.7)Operating income, Q2 FY2025, three months to 2025-06-30−$7.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure(10.7)Operating income, Q3 FY2025, three months to 2025-09-30−$10.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure(7.9)Operating income, Q4 FY2025, three months to 2025-12-31−$7.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure23.3Operating income, Q1 FY2026, three months to 2026-03-31$23.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure(13.9)Operating income, Q2 FY2026, three months to 2026-06-30−$13.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Interest expense$m0.0Interest expense, Q3 FY2023, three months to 2023-09-30$4.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0001641489-23-000070.Report this figure0.0Interest expense, Q4 FY2023, three months to 2023-12-31$7.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-13, accession 0001641489-24-000012. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2024, three months to 2024-03-31$100.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Net income$m(6.7)Net income, Q3 FY2023, three months to 2023-09-30−$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure(3.5)Net income, Q4 FY2023, three months to 2023-12-31−$3.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure(4.9)Net income, Q1 FY2024, three months to 2024-03-31−$4.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure(5.2)Net income, Q2 FY2024, three months to 2024-06-30−$5.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure(4.8)Net income, Q3 FY2024, three months to 2024-09-30−$4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure(3.6)Net income, Q4 FY2024, three months to 2024-12-31−$3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure(5.1)Net income, Q1 FY2025, three months to 2025-03-31−$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure(6.0)Net income, Q2 FY2025, three months to 2025-06-30−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure(8.7)Net income, Q3 FY2025, three months to 2025-09-30−$8.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure(7.1)Net income, Q4 FY2025, three months to 2025-12-31−$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure24.1Net income, Q1 FY2026, three months to 2026-03-31$24.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure(13.1)Net income, Q2 FY2026, three months to 2026-06-30−$13.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure

Balance sheet

Cash and equivalents$86.6m, Q2 FY2026
Shareholders' equity$78.6m, Q2 FY2026
vTv Therapeutics Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m8.2Cash and equivalents, Q3 FY2023, at 2023-09-30$8.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001641489-23-000070.Report this figure9.4Cash and equivalents, FY2023, at 2023-12-31$9.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure52.3Cash and equivalents, Q1 FY2024, at 2024-03-31$52.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001641489-24-000029.Report this figure45.5Cash and equivalents, Q2 FY2024, at 2024-06-30$45.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001641489-24-000061.Report this figure41.6Cash and equivalents, Q3 FY2024, at 2024-09-30$41.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure36.7Cash and equivalents, FY2024, at 2024-12-31$36.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure31.1Cash and equivalents, Q1 FY2025, at 2025-03-31$31.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure25.9Cash and equivalents, Q2 FY2025, at 2025-06-30$25.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure98.5Cash and equivalents, Q3 FY2025, at 2025-09-30$98.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure88.9Cash and equivalents, FY2025, at 2025-12-31$88.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure98.1Cash and equivalents, Q1 FY2026, at 2026-03-31$98.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure86.6Cash and equivalents, Q2 FY2026, at 2026-06-30$86.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Current assets$m10.1Current assets, Q3 FY2023, at 2023-09-30$10.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001641489-23-000070.Report this figure10.7Current assets, FY2023, at 2023-12-31$10.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure53.9Current assets, Q1 FY2024, at 2024-03-31$53.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001641489-24-000029.Report this figure46.2Current assets, Q2 FY2024, at 2024-06-30$46.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001641489-24-000061.Report this figure43.0Current assets, Q3 FY2024, at 2024-09-30$43.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure38.1Current assets, FY2024, at 2024-12-31$38.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure31.9Current assets, Q1 FY2025, at 2025-03-31$31.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure26.4Current assets, Q2 FY2025, at 2025-06-30$26.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure99.5Current assets, Q3 FY2025, at 2025-09-30$99.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure89.9Current assets, FY2025, at 2025-12-31$89.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure98.8Current assets, Q1 FY2026, at 2026-03-31$98.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure87.6Current assets, Q2 FY2026, at 2026-06-30$87.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Total assets$m14.9Total assets, Q3 FY2023, at 2023-09-30$14.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001641489-23-000070.Report this figure11.0Total assets, FY2023, at 2023-12-31$11.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure54.2Total assets, Q1 FY2024, at 2024-03-31$54.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001641489-24-000029.Report this figure46.5Total assets, Q2 FY2024, at 2024-06-30$46.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001641489-24-000061.Report this figure43.2Total assets, Q3 FY2024, at 2024-09-30$43.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure38.3Total assets, FY2024, at 2024-12-31$38.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure32.0Total assets, Q1 FY2025, at 2025-03-31$32.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure26.4Total assets, Q2 FY2025, at 2025-06-30$26.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure99.5Total assets, Q3 FY2025, at 2025-09-30$99.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure89.9Total assets, FY2025, at 2025-12-31$89.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure98.8Total assets, Q1 FY2026, at 2026-03-31$98.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure87.6Total assets, Q2 FY2026, at 2026-06-30$87.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Current liabilities$m10.3Current liabilities, Q3 FY2023, at 2023-09-30$10.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001641489-23-000070.Report this figure10.6Current liabilities, FY2023, at 2023-12-31$10.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure8.9Current liabilities, Q1 FY2024, at 2024-03-31$8.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001641489-24-000029.Report this figure7.0Current liabilities, Q2 FY2024, at 2024-06-30$7.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001641489-24-000061.Report this figure6.4Current liabilities, Q3 FY2024, at 2024-09-30$6.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure5.2Current liabilities, FY2024, at 2024-12-31$5.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure4.3Current liabilities, Q1 FY2025, at 2025-03-31$4.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure5.3Current liabilities, Q2 FY2025, at 2025-06-30$5.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure10.2Current liabilities, Q3 FY2025, at 2025-09-30$10.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure6.6Current liabilities, FY2025, at 2025-12-31$6.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure6.9Current liabilities, Q1 FY2026, at 2026-03-31$6.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure7.0Current liabilities, Q2 FY2026, at 2026-06-30$7.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Total liabilities$m29.4Total liabilities, Q3 FY2023, at 2023-09-30$29.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001641489-23-000070.Report this figure29.6Total liabilities, FY2023, at 2023-12-31$29.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure28.2Total liabilities, Q1 FY2024, at 2024-03-31$28.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001641489-24-000029.Report this figure26.0Total liabilities, Q2 FY2024, at 2024-06-30$26.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001641489-24-000061.Report this figure25.3Total liabilities, Q3 FY2024, at 2024-09-30$25.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure24.0Total liabilities, FY2024, at 2024-12-31$24.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure23.1Total liabilities, Q1 FY2025, at 2025-03-31$23.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure24.0Total liabilities, Q2 FY2025, at 2025-06-30$24.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure29.0Total liabilities, Q3 FY2025, at 2025-09-30$29.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure25.5Total liabilities, FY2025, at 2025-12-31$25.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure8.9Total liabilities, Q1 FY2026, at 2026-03-31$8.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure9.0Total liabilities, Q2 FY2026, at 2026-06-30$9.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(25.2)Shareholders' equity, Q3 FY2023, at 2023-09-30−$25.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-09, accession 0001641489-23-000070.Report this figure(24.7)Shareholders' equity, FY2023, at 2023-12-31−$24.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure20.8Shareholders' equity, Q1 FY2024, at 2024-03-31$20.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-05-09, accession 0001641489-24-000029.Report this figure16.5Shareholders' equity, Q2 FY2024, at 2024-06-30$16.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-08-08, accession 0001641489-24-000061.Report this figure15.0Shareholders' equity, Q3 FY2024, at 2024-09-30$15.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001641489-24-000075.Report this figure12.2Shareholders' equity, FY2024, at 2024-12-31$12.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure7.9Shareholders' equity, Q1 FY2025, at 2025-03-31$7.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure2.8Shareholders' equity, Q2 FY2025, at 2025-06-30$2.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-12, accession 0001641489-25-000053.Report this figure70.5Shareholders' equity, Q3 FY2025, at 2025-09-30$70.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure64.4Shareholders' equity, FY2025, at 2025-12-31$64.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure90.0Shareholders' equity, Q1 FY2026, at 2026-03-31$90.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure78.6Shareholders' equity, Q2 FY2026, at 2026-06-30$78.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure

Cash flow

Operating cash flow−$11.4m, Q2 FY2026
Capital expenditure$0, Q4 FY2023
vTv Therapeutics Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(4.8)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001641489-24-000075. Derived: 9-month figure less the 6-month figure.Report this figure(2.9)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure(7.3)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$7.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001641489-25-000026.Report this figure(6.7)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001641489-25-000053. Derived: 6-month figure less the 3-month figure.Report this figure(6.4)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$6.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001641489-25-000060. Derived: 9-month figure less the 6-month figure.Report this figure(4.8)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure(5.7)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure(5.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001641489-26-000030. Derived: 6-month figure less the 3-month figure.Report this figure(5.2)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001641489-25-000060. Derived: 9-month figure less the 6-month figure.Report this figure(9.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$9.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure9.2Operating cash flow, Q1 FY2026, three months to 2026-03-31$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure(11.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$11.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001641489-26-000030. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-11-09, accession 0001641489-23-000070. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001641489-25-000014. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.